海外业务的高韧性成为业绩增长的重要驱动力。今年上半年，公司持续经营收入204.1亿元，海外客户 收入占比约85%。其中，来自美国客户的收入有140.3亿元，同比增长38.4%；来自欧洲客户的收入有 23.3亿元，同比增长9.2%。 信达证券研报指出，从2024年生物安全法案到2025年中美关税冲突，市场对于地缘政治风险的担忧已经 充分演绎，2025年H1公司来自美国客户的业务增速依然强劲，再次打消市场疑虑，全球化趋势难以抵 挡，公司在全球产业链中地位稳健。 细分业务中，TIDES（寡核苷酸和多肽）表现尤为亮眼。上半年，药明康德TIDES业务保持高速增长， 成为拉动业绩的关键因素之一。其业务收入50.3亿元，同比增长1.42倍，约占公司整体收入的24%。 7月29日，药明康德港股涨超11%，带动今日港股CRO板块逆势走强，泰格医药涨超9%，昭衍新药涨超 9%，康龙化成涨超7%。板块集体上扬的背后，是药明康德前一日发布的半年报数据为市场注入强心 针。 前一日晚间，药明康德公布2025年半年报。药明康德上半年营业收入208亿元，同比增长20.6%。归母 净利润85.61亿元，同比增长101.9%。今年上半年，公司持 ...

Core Viewpoint - WuXi AppTec (2359.HK) reported better-than-expected performance in the first half of the year, with revenue reaching 20.8 billion yuan, a year-on-year increase of 20.6% [1] - Net profit increased by 102% year-on-year to 8.6 billion yuan, while recurring net profit, excluding a one-time gain of 3.3 billion yuan from the sale of WuXi AppTec's stake, grew by 26.5% to 5.9 billion yuan [1] Financial Performance - Revenue for the first half of the year was 20.8 billion yuan, reflecting a 20.6% year-on-year growth [1] - Net profit surged by 102% year-on-year to 8.6 billion yuan [1] - Recurring net profit increased by 26.5% to 5.9 billion yuan when excluding one-time gains [1] Guidance and Projections - Management raised the full-year revenue guidance by 2% to a range of 42.5 billion to 43.5 billion yuan [1] - Free cash flow guidance was increased by 22% to a range of 5 billion to 6 billion yuan [1] - Capital expenditure budget remains unchanged at 7 billion to 8 billion yuan [1] Business Segments - TIDES business revenue grew by 142% year-on-year to 5 billion yuan, driven by GLP-1 raw material drugs, exceeding the annual growth target of 60% [1] - The second quarter gross margin reached a new high of 46.9%, attributed to improved production efficiency in the chemical business and an increase in later-stage projects [1] - However, only 8 new commercialization and phase III projects were added in the first half, and the China business experienced a year-on-year decline of 5% [1] Analyst Rating - The firm reiterated an outperform rating with a target price of 116 HKD [1]

Core Viewpoint - The report from Cinda Securities indicates that WuXi AppTec's TEDIS business is experiencing high growth, leading to an upward revision of the company's annual performance guidance [1] Financial Performance - In H1 2025, the company is expected to achieve a net profit attributable to shareholders of approximately 8.56 billion yuan, representing a year-on-year growth of 101.9% [1] - In Q2 2025, the adjusted net profit attributable to shareholders is projected to be 3.64 billion yuan, reflecting a year-on-year increase of 47.9% [1] Business Growth Drivers - The strong growth in the company's chemical business is primarily driven by the high demand in the TEDIS segment [1] - The demand for peptides and oligonucleotides remains robust, with a rich order backlog [1] - The company plans to increase its peptide solid-phase synthesis capacity to over 100,000 liters by the end of 2025, indicating a positive outlook for the next 1-2 years [1] Global Market Position - Approximately 85% of the company's revenue comes from overseas clients, establishing it as a fully globalized and competitive leader in the CRDMO sector [1] - Despite geopolitical concerns, the business growth from U.S. clients remains strong in H1 2025, alleviating market worries [1] - The global trend is expected to continue, with the company maintaining a solid position in the global supply chain [1]

Major Events - Xizang Tianlu announced that its convertible bond "Tianlu Convertible Bond" experienced significant abnormal trading fluctuations, with a cumulative closing price increase of over 100% from July 21 to July 29, 2025, closing at 481.80 yuan per bond, representing a premium of 381.80% over the face value and a conversion premium rate of 16.60% [1] - Huqin Technology plans to acquire 6% of Jinghe Integrated's shares for 2.393 billion yuan, purchasing 120 million shares at a price of 19.88 yuan per share, marking its first stake in the company [2] - Liyuan Technology's actual controller, Shen Wanzhong, received a criminal judgment for violating information disclosure regulations, sentenced to one year in prison with a one and a half year probation, and fined 3.3 million yuan, but this will not significantly impact the company's operations [3] - Huashi Technology announced the lifting of detention measures against its actual controller and general manager, Ye Jianbiao, allowing him to resume his duties [4] - Dongfang Materials' chairman, Xu Guangbin, resigned due to personal reasons but will continue as a board member [5] - WuXi AppTec adjusted its share repurchase price limit from 90.72 yuan to 114.15 yuan per share [6] Performance Overview - Greenland Holdings reported a contract sales amount of 21.752 billion yuan in Q2 2025, a year-on-year increase of 16.93%, with a total sales area of 2.217 million square meters, up 31.03% from the previous year [7] - Lujiazui's H1 2025 net profit was 815 million yuan, a decrease of 7.87%, despite a revenue increase of 33.91% to 6.598 billion yuan [8] - Hongfa Co. achieved a net profit of 964 million yuan in H1 2025, a year-on-year increase of 14.19%, with revenue of 8.347 billion yuan, up 15.43% [9] - Nanya New Materials expects a net profit of 80 million to 95 million yuan in H1 2025, representing a year-on-year increase of 44.69% to 71.82% due to increased sales and improved product structure [9] - Sains expects a net profit decline of 57.53% to 60.13% in H1 2025, with revenue between 410 million and 440 million yuan, a year-on-year increase of 15.17% to 23.59% [9] - Baotai anticipates a net loss of 110 million to 140 million yuan in H1 2025, a reduction in losses compared to the previous year, attributed to increased sales of a specific product and reduced R&D expenses [9] Major Contracts - China CNR announced the signing of several major contracts totaling approximately 32.92 billion yuan, accounting for 13.4% of its projected revenue for 2024 [10] - Wantong Zhikong signed an exclusive authorization agreement with Shanghai Shenming Aosi Semiconductor Technology for the sales and cooperation in the field of embodied intelligence [11] - Anhui Construction won a bid for a highway concession project in Chongqing, with an estimated total investment of 3.614 billion yuan [11] Shareholding Changes - Jiahe Meikang's shareholder, Guoshou Chengda, plans to reduce its stake by up to 3% through various trading methods [12] - Lanfeng Biochemical's shareholder, Hainan Wenqin, intends to reduce its stake by up to 2.61% [12]

| 综合屏 F9 前复权 超级叠加 画线 工具 Q ? | | | 矢约ETF | | 159929 | | --- | --- | --- | --- | --- | --- | | €1.434 均1.464 量190万 换13.74% 振2.98% 额2.79亿 | 2024/12/11-2025/07/29(153日)▼ | | 1 2 11 1 | | +0.028 +1.94% | | | | | SZSE CNY 15:00:06 闭市 | | 通融入口中 | | 1.477- | 1.470 | | 净值走势 | 汇添富中证医药卫生ETF | | | | | | रुक्त 16.02% 120日 | | 21.19% | | | | | 5日 5.76% 250日 | | 24.16% | | | 1.410 | | 20日 11.62% 52周高 | | 1.56 | | | | | 60日 17.41% 52周低 | | 1.08 | | | 1.350 | | 实时申购赎回信息 | 申购 | 岐回 | | | | | 笔数 | વેર | 31 | | | | | 金额 | 0 | 0 ...

药明康德（603259）(02359)公布，公司于2025年7月 29 日召开第三届董事会第二十三次会议，审议通 过了《关于调整回购股份价格上限的议案》，公司拟将 2025 年第一次以集中竞价交易方式回购A股股 份的回购股份价格上限由不超过 90.72 元/股(含)调整为不超过人民币 114.15 元/股，本次回购方案的其 他内容不变。 ...

医药医疗加快上行脚步！A股最大医疗ETF（512170）今日（2025年7月29日）刷新多项纪录：收涨2.45%报0.377元，收盘价创去年"924"以来次高！日线豪 取10连阳，刷新历史最长连阳纪录！全天成交11.52亿元，为近3个月次高。 制药板块同步活跃，国内首只药ETF（562050）盘中摸高2%，场内收涨1.68%，收盘价续创上市以来新高。百亿美元出海大单加持，核心权重股恒瑞医药继 昨日涨停后续涨2.84%，成交107.31亿元，跻身A股前三。 图片来源： 企业供图 药明康德交出"史上最强"半年报，CXO板块沸腾！医疗ETF（512170）覆盖的6只CXO龙头股集体上攻，药明康德涨7.72%，股价逼近100元，创3年新高！成 交90.14亿元，位列A股第7。此外，九洲药业涨停，昭衍新药午后触板。 中金公司指出，如今创新药板块估值中枢上修，预期BD资金和二级热度上涨将反哺国内新药研发需求起量以及一级创新药项目融资活跃度提升，内需CRO 有望受益。另一方面，中国企业成本与效率优势对海外客户具较强吸引力，外需CDMO订单趋势同样向好。 中泰证券提示，随着财报陆续披露，CXO、GLP-1等景气赛道表现亮眼。 ...

里昂发布研报称，将药明康德（02359）目标价从92.40港元上调至113.70港元；药明康德（603259.SH） 目标价从92.40元人民币上调至103.40元人民币，维持"跑赢大市"投资评级。 药明康德2025年第二季收入及经调整非国际财务报告准则净利润分别同比增长20%及48%，符合2025年 7月10日发布的盈利预告。公司将2025年持续经营业务收入增长指引，从10%至15%上调至13%至17%， 自由现金流指引从40亿元至50亿元人民币，上调到50亿元至60亿元人民币。考虑到上半年强劲表现，上 调后的收入指引并不显激进，并重申2025年经调整非国际财务报告准则净利润率将较2024年有所改善。 里昂相应上调药明康德2025至2027年全年收入及净利润预测，幅度分别为3%至4%及13%至17%，以反 映最新指引。 来源：新浪港股 ...

药明康德(02359)公布，公司于2025年7月 29 日召开第三届董事会第二十三次会议，审议通过了《关于 调整回购股份价格上限的议案》，公司拟将 2025 年第一次以集中竞价交易方式回购A股股份的回购股 份价格上限由不超过 90.72 元/股(含)调整为不超过人民币 114.15 元/股，本次回购方案的其他内容不 变。 ...

Market Overview - A-shares experienced a significant afternoon rally, with the Shanghai Composite Index regaining above 3600 points, closing up 0.33% at 3609.71 points, while the ChiNext Index rose nearly 2% to 2406.59 points, marking a new high for the year [1] - The total trading volume in the Shanghai and Shenzhen markets reached 182.96 billion yuan, an increase of approximately 63 billion yuan compared to the previous day [1] Sector Performance - The insurance and banking sectors saw declines, while the semiconductor sector surged, with Dongxin Co. hitting a 20% limit up and Fudan Microelectronics rising nearly 10% [1] - The steel sector also showed strong performance, with Xining Special Steel and Bayi Steel reaching their daily limit up [1] - The innovative drug concept experienced a resurgence, with Sanmiao Gene rising over 20% and several other pharmaceutical stocks hitting their daily limit up [1][3] Notable Stocks - WuXi AppTec reported a 96.20% year-on-year increase in total profit and a 101.92% increase in net profit attributable to shareholders for the first half of the year, with a backlog of orders amounting to 56.69 billion yuan, a 37.2% increase year-on-year [4][5] - The stock of Weiwai New Materials surged over 10 times since July, reaching a new high of 90 yuan per share, although the company cautioned that its stock price has significantly deviated from its fundamental situation [10] Future Outlook - WuXi AppTec expects its revenue from ongoing operations to return to double-digit growth, with an upward adjustment of its overall revenue forecast to between 42.5 billion and 43.5 billion yuan [5] - The innovative drug industry is anticipated to enter a new phase, with significant opportunities expected in 2025, driven by upcoming international conferences and ongoing licensing transactions [6] Semiconductor Sector Insights - The semiconductor sector saw strong gains, with Dongxin Co. and Fudan Microelectronics leading the charge [7] - The U.S. government's recent AI Action Plan aims to bolster domestic semiconductor manufacturing while imposing restrictions on exports, which may accelerate the domestic industry's self-sufficiency [9]